Editas Medicine received regulatory approval to begin a Phase 1/2 clinical trial of its gene-editing therapy EDIT-401 in patients with hyperlipidemia, specifically targeting those with Heterozygous Familial Hypercholesterolemia (HeFH) in Australia and potentially New Zealand. EDIT-401 aims to reduce LDL cholesterol by editing the LDLR gene, showing promising preclinical results with up to 90% reduction in LDL-C and other harmful lipoproteins. The trial will assess safety, tolerability, and efficacy, with initial patient dosing expected in 2026 and early data anticipated in the first quarter of 2027. New preclinical data will also be presented at the American Heart Association Scientific Sessions in November 2026, highlighting the drug's potential for durable cholesterol reduction.
Editas Medicine's new gene-editing therapy trial news comes with this market context for readers following health stocks: Of 100 priced US health-sector stocks on Pluang, 25 advanced and 68 declined as of Oct 08, 2026 18:11 WIB. Notable movers include RXRX at USD 4.15 with a 2.81% decrease and 95% sell order activity, HRTX at USD 0.38 with a 2.56% drop and 70% buy order activity, and TWST at USD 151.90 down 2.41% with 97% buy order activity. Typical hold times range from 22 to 35 days among these stocks.
Dividend 15 Split Corp. has renewed its at-the-market (ATM) equity program, allowing it to issue shares to the public at prevailing market prices until November 7, 2028. This program replaces the previous one that ended in 2025 and enables the compan...
Fieldstone Bio, a synthetic biology company, was selected for the Mining Tech Accelerator program by Founders Factory and Rio Tinto. The program supports innovative technologies that improve mineral exploration and extraction, providing Fieldstone wi...
Beam Global has signed a definitive agreement to acquire ScoutDI, a company specializing in drone technology and AI-powered inspection software. The acquisition will enable Beam to manufacture ScoutDI's drone systems in the US and Europe, targeting i...
Grabar Law Office is investigating shareholder claims against four companies—Aardvark Therapeutics, Coastal Financial Corporation, Erasca, Inc., and New Era Energy & Digital—for alleged securities violations and breaches of fiduciary duties. The clai...
Visa Canada's data reveals that the Toronto International Film Festival (TIFF) 2026 increased visitor spending by 12% compared to 2025, with international visitors spending about 40% more than Canadian cardholders. The festival attracted visitors mai...
